No Abstract Assistant Managing EditorDanish biotech firm Zealand Pharma A/S partnered with Helsinn Healthcare in a potential €140 million (US$176.8 million) deal to develop its early clinical-stage glucagon-like peptide (GLP)-2 receptor agonist, ZP1846, in chemotherapy-induced diarrhea (CID).Under the terms, Zealand granted Helsinn worldwide rights to the compound, except for the Nordic countries, where Zealand retains marketing rights.

Danish biotech firm Zealand Pharma A/S partnered with Helsinn Healthcare in a potential €140 million (US$176.8 million) deal to develop its early clinical-stage glucagon-like peptide (GLP)-2 receptor agonist, ZP1846, in chemotherapy-induced diarrhea (CID). (BioWorld Today) 

Two months after urging shareholders to reject a $37-per-share offer from King Pharmaceuticals Inc., Alpharma Inc. changed its mind and agreed to the merger, which values the specialty pharma firm at about $1.6 billion. (BioWorld Today)

Despite United Therapeutics Corp.'s best efforts to put a positive spin on its oral pulmonary arterial hypertension (PAH) program by highlighting a recent in-licensing deal for Eli Lilly and Co.'s late-stage tadalafil, the company's shares sank 35 percent on a Phase III miss with its own oral PAH drug. (BioWorld Today)

A holding firm has put an offer on the table to buy out Canadian biotech YM BioSciences Inc., a company that, despite two late-stage products in its pipeline, has been pining for attention from an increasingly tough capital market. (BioWorld Today)